# Carmine Giorgio

List of Publications by Year
in descending order



| 30 | 719 | 430874 18 | 526287 27 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 30 | 30 | 30 | 984 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Protein-Protein Interaction Inhibitors Targeting the Eph-Ephrin System with a Focus on Amino Acid Conjugates of Bile Acids. Pharmaceuticals, 2022, 15, 137. | 3.8 | 5 |
| 2 | Metabolic Soft Spot and Pharmacokinetics: Functionalization of C-3 Position of an Ephâ€“Ephrin Antagonist Featuring a Bile Acid Core as an Effective Strategy to Obtain Oral Bioavailability in Mice. Pharmaceuticals, 2022, 15, 41. | 3.8 | 2 |
| 3 | UniPR1331: Small Eph/Ephrin Antagonist Beneficial in Intestinal Inflammation by Interfering with Type-B Signaling. Pharmaceuticals, 2021, 14, 502. | 3.8 | 2 |
| 4 | Drug-gut microbiota metabolic interactions: the case of UniPR1331, selective antagonist of the Eph-ephrin system, in mice. Journal of Pharmaceutical and Biomedical Analysis, 2020, 180, 113067. | 2.8 | 5 |
| 5 | Ephrin or not? Six tough questions on Eph targeting. Expert Opinion on Therapeutic Targets, 2020, 24, 403-415. | 3.4 | 10 |
| 6 | Optimization of EphA2 antagonists based on a lithocholic acid core led to the identification of UniPR505, a new 3Î±-carbamoyloxy derivative with antiangiogenetic properties. European Journal of Medicinal Chemistry, 2020, 189, 112083. | 5.5 | 5 |
| 7 | Evaluation of the Anti-Tumor Activity of Small Molecules Targeting Eph/Ephrins in APC min/J Mice. Pharmaceuticals, 2020, 13, 69. | 3.8 | 0 |
| 8 | Targeting the Eph/Ephrin System as Anti-Inflammatory Strategy in IBD. Frontiers in Pharmacology, 2019, 10, 691. | 3.5 | 22 |
| 9 | Pharmacological evaluation of new bioavailable small molecules targeting Eph/ephrin interaction. Biochemical Pharmacology, 2018, 147, 21-29. | 4.4 | 20 |
| 10 | UniPR1331, a small molecule targeting Eph/ephrin interaction, prolongs survival in glioblastoma and potentiates the effect of antiangiogenic therapy in mice. Oncotarget, 2018, 9, 24347-24363. | 1.8 | 28 |
| 11 | Metadynamics for Perspective Drug Design: Computationally Driven Synthesis of New Proteinâ€“Protein Interaction Inhibitors Targeting the EphA2 Receptor. Journal of Medicinal Chemistry, 2017, 60, 787-796. | 6.4 | 32 |
| 12 | Targeting Eph/ephrin system in cancer therapy. European Journal of Medicinal Chemistry, 2017, 142, 152-162. | 5.5 | 80 |
| 13 | Exploiting Freeâ€Energy Minima to Design Novel EphA2 Proteinâ€“Protein Antagonists: From Simulation to Experiment and Return. Chemistry - A European Journal, 2016, 22, 8048-8052. | 3.3 | 15 |
| 14 | Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis. Biochemical Pharmacology, 2016, 99, 18-30. | 4.4 | 6 |
| 15 | The ellagitannin colonic metabolite urolithin D selectively inhibits EphA2 phosphorylation in prostate cancer cells. Molecular Nutrition and Food Research, 2015, 59, 2155-2167. | 3.3 | 31 |
| 16 | Studies on the antiplatelet and antithrombotic profile of anti-inflammatory coumarin derivatives. Journal of Enzyme Inhibition and Medicinal Chemistry, 2015, 30, 925-933. | 5.2 | 33 |
| 17 | Î”5-Cholenoyl-amino acids as selective and orally available antagonists of the Ephâ€“ephrin system. European Journal of Medicinal Chemistry, 2015, 103, 312-324. | 5.5 | 38 |
| 18 | Target Hopping as a Useful Tool for the Identification of Novel EphA2 Proteinâ€“Protein Antagonists. ChemMedChem, 2014, 9, 67-72. | 3.2 | 27 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Therapeutic perspectives of Ephâ€“ephrin system modulation. Drug Discovery Today, 2014, 19, 661-669. | 6.4 | 38 |
| 20 | Combining Ligand- and Structure-Based Approaches for the Discovery of New Inhibitors of the EPHA2â€“ephrin-A1 Interaction. Journal of Chemical Information and Modeling, 2014, 54, 2621-2626. | 5.4 | 13 |
| 21 | 1,8-Naphthyridines IX. Potent anti-inflammatory and/or analgesic activity of a new group of substituted 5-amino[1,2,4]triazolo[4,3-a][1,8]naphthyridine-6-carboxamides, of some their Mannich base derivatives and of one novel substituted 5-amino-10-oxo-10H-pyrimido[1,2-a][1,8]naphthyridine-6-carboxamide derivative. European Journal of Medicinal Chemistry, 2014, 86, 394-405. | 5.5 | 24 |
| 22 | Amino Acid Conjugates of Lithocholic Acid As Antagonists of the EphA2 Receptor. Journal of Medicinal Chemistry, 2013, 56, 2936-2947. | 6.4 | 50 |
| 23 | Synthesis and Structure-Activity Relationships of Amino Acid Conjugates of Cholanic Acid as Antagonists of the EphA2 Receptor. Molecules, 2013, 18, 13043-13060. | 3.8 | 13 |
| 24 | Perturbation of the EphA2â€“EphrinA1 System in Human Prostate Cancer Cells by Colonic (Poly)phenol Catabolites. Journal of Agricultural and Food Chemistry, 2012, 60, 8877-8884. | 5.2 | 25 |
| 25 | Structureâ€“Activity Relationships and Mechanism of Action of Ephâ€“ephrin Antagonists: Interaction of Cholanic Acid with the EphA2 Receptor. ChemMedChem, 2012, 7, 1071-1083. | 3.2 | 31 |
| 26 | Synthesis of new 5,6-dihydrobenzo[h]quinazoline 2,4-diamino substituted and antiplatelet/antiphlogistic activities evaluation. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 1125-1129. | 2.2 | 17 |
| 27 | Polyphenol rich botanicals used as food supplements interfere with EphA2â€“ephrinA1 system. Pharmacological Research, 2011, 64, 464-470. | 7.1 | 19 |
| 28 | Lithocholic Acid Is an Eph-ephrin Ligand Interfering with Eph-kinase Activation. PLoS ONE, 2011, 6, e18128. | 2.5 | 66 |
| 29 | Ocotea quixos Lam. essential oil: In vitro and in vivo investigation on its anti-inflammatory properties. FÃ¬toterapÃ¬Ã¢, 2010, 81, 289-295. | 2.2 | 41 |
| 30 | 1-Methyl and 1-(2-hydroxyalkyl)-5-(3-alkyl/cycloalkyl/phenyl/naphthylureido)-1H-pyrazole-4-carboxylic acid ethyl esters as potent human neutrophil chemotaxis inhibitors. Bioorganic and Medicinal Chemistry, 2009, 17, 3379-3387. | 3.0 | 21 |